91 related articles for article (PubMed ID: 8080205)
1. Invariant chain dissociation from class II MHC is a catalyst for foreign peptide binding.
Reyes VE; Daibata M; Espejo R; Humphreys RE
Ann N Y Acad Sci; 1994 Aug; 730():338-41. PubMed ID: 8080205
[No Abstract] [Full Text] [Related]
2. More efficient peptide binding to MHC class II molecules during cathepsin B digestion of Ii than after Ii release.
Daibata M; Xu M; Humphreys RE; Reyes VE
Mol Immunol; 1994 Mar; 31(4):255-60. PubMed ID: 8139580
[TBL] [Abstract][Full Text] [Related]
3. Cathepsin B cleavage of Ii from class II MHC alpha- and beta-chains.
Reyes VE; Lu S; Humphreys RE
J Immunol; 1991 Jun; 146(11):3877-80. PubMed ID: 2033257
[TBL] [Abstract][Full Text] [Related]
4. DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide.
Sherman MA; Weber DA; Jensen PE
Immunity; 1995 Aug; 3(2):197-205. PubMed ID: 7648393
[TBL] [Abstract][Full Text] [Related]
5. Cathepsin B cleavage and release of invariant chain from MHC class II molecules follow a staged pattern.
Xu M; Capraro GA; Daibata M; Reyes VE; Humphreys RE
Mol Immunol; 1994 Jul; 31(10):723-31. PubMed ID: 8035834
[TBL] [Abstract][Full Text] [Related]
6. Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM.
Weber DA; Evavold BD; Jensen PE
Science; 1996 Oct; 274(5287):618-20. PubMed ID: 8849454
[TBL] [Abstract][Full Text] [Related]
7. Release of DR molecules from complexes with invariant chain through the formation of a C-terminal 25 kDa invariant chain fragment.
Demotz S; Danieli C
Mol Immunol; 1993 Dec; 30(18):1623-32. PubMed ID: 8272076
[TBL] [Abstract][Full Text] [Related]
8. Delivery of nascent MHC class II-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells.
Morton PA; Zacheis ML; Giacoletto KS; Manning JA; Schwartz BD
J Immunol; 1995 Jan; 154(1):137-50. PubMed ID: 7995933
[TBL] [Abstract][Full Text] [Related]
9. A mutant human histocompatibility leukocyte antigen DR molecule associated with invariant chain peptides.
Mellins E; Cameron P; Amaya M; Goodman S; Pious D; Smith L; Arp B
J Exp Med; 1994 Feb; 179(2):541-9. PubMed ID: 8294865
[TBL] [Abstract][Full Text] [Related]
10. Glycoprotein B from strain 17 of herpes simplex virus type I contains an invariant chain homologous sequence that binds to MHC class II molecules.
Sievers E; Neumann J; Raftery M; SchOnrich G; Eis-Hübinger AM; Koch N
Immunology; 2002 Sep; 107(1):129-35. PubMed ID: 12225371
[TBL] [Abstract][Full Text] [Related]
11. Rheumatoid arthritis (RA)-associated HLA-DR alleles form less stable complexes with class II-associated invariant chain peptide than non-RA-associated HLA-DR alleles.
Patil NS; Pashine A; Belmares MP; Liu W; Kaneshiro B; Rabinowitz J; McConnell H; Mellins ED
J Immunol; 2001 Dec; 167(12):7157-68. PubMed ID: 11739539
[TBL] [Abstract][Full Text] [Related]
12. Mediation by HLA-DM of dissociation of peptides from HLA-DR.
Sloan VS; Cameron P; Porter G; Gammon M; Amaya M; Mellins E; Zaller DM
Nature; 1995 Jun; 375(6534):802-6. PubMed ID: 7596415
[TBL] [Abstract][Full Text] [Related]
13. HLA-DM is present in one-fifth the amount of HLA-DR in the class II peptide-loading compartment where it associates with leupeptin-induced peptide (LIP)-HLA-DR complexes.
Schafer PH; Green JM; Malapati S; Gu L; Pierce SK
J Immunol; 1996 Dec; 157(12):5487-95. PubMed ID: 8955198
[TBL] [Abstract][Full Text] [Related]
14. Editing of the HLA-DR-peptide repertoire by HLA-DM.
Kropshofer H; Vogt AB; Moldenhauer G; Hammer J; Blum JS; Hämmerling GJ
EMBO J; 1996 Nov; 15(22):6144-54. PubMed ID: 8947036
[TBL] [Abstract][Full Text] [Related]
15. Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways.
Teyton L; O'Sullivan D; Dickson PW; Lotteau V; Sette A; Fink P; Peterson PA
Nature; 1990 Nov; 348(6296):39-44. PubMed ID: 2234057
[TBL] [Abstract][Full Text] [Related]
16. In vivo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides.
Avva RR; Cresswell P
Immunity; 1994 Dec; 1(9):763-74. PubMed ID: 7895165
[TBL] [Abstract][Full Text] [Related]
17. Supermotifs enable natural invariant chain-derived peptides to interact with many major histocompatibility complex-class II molecules.
Malcherek G; Gnau V; Jung G; Rammensee HG; Melms A
J Exp Med; 1995 Feb; 181(2):527-36. PubMed ID: 7836909
[TBL] [Abstract][Full Text] [Related]
18. Dissection of the HLA-DR4 peptide repertoire in endocrine epithelial cells: strong influence of invariant chain and HLA-DM expression on the nature of ligands.
Muntasell A; Carrascal M; Alvarez I; Serradell L; van Veelen P; Verreck FA; Koning F; Abian J; Jaraquemada D
J Immunol; 2004 Jul; 173(2):1085-93. PubMed ID: 15240697
[TBL] [Abstract][Full Text] [Related]
19. Structural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition of peptide binding.
Kropshofer H; Vogt AB; Hämmerling GJ
Proc Natl Acad Sci U S A; 1995 Aug; 92(18):8313-7. PubMed ID: 7667286
[TBL] [Abstract][Full Text] [Related]
20. Assembly of major histocompatibility complex class II subunits with invariant chain.
Neumann J; Koch N
FEBS Lett; 2005 Nov; 579(27):6055-9. PubMed ID: 16242130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]